Eli Lilly and Company’s Stock Price Soars to $949.97, Witnessing an Impressive 3.05% Uptick

Eli Lilly and Company (LLY)

949.97 USD +28.16 (+3.05%) Volume: 4.94M

Eli Lilly and Company’s stock price soared to 949.97 USD, marking a significant trading session increase of +3.05%, with a robust trading volume of 4.94M. The pharmaceutical giant has impressively surged +62.97% YTD, demonstrating a strong performance in the stock market.

Latest developments on Eli Lilly and Company

Eli Lilly & Company’s stock price soared to a record high on Tuesday following the success of their weight-loss drug, tirzepatide, in reducing the risk of developing type 2 diabetes by a staggering 94% in adults with pre-diabetes and obesity or overweight. This news comes after the company announced plans to test their drug, Zepbound, in treating psoriasis, building on the momentum of their weight-loss blockbuster that has shown promising results in preventing diabetes. Analysts and investors have shown strong confidence in Eli Lilly’s future, with Jim Cramer expressing his faith in the company’s growth potential. With the recent positive study data and market performance, Eli Lilly & Company continues to be a top contender in the pharmaceutical industry, driving their stock price to new heights.

A look at Eli Lilly and Company Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Eli Lilly & Company has a positive long-term outlook. With a Momentum score of 4, the company is showing strong performance trends that indicate potential future growth. Additionally, a Growth score of 3 suggests that Eli Lilly & is positioned for continued expansion in the pharmaceutical industry. While the company’s Value, Dividend, and Resilience scores are not as high, the overall outlook remains promising.

Eli Lilly & Company is a global pharmaceutical company that focuses on discovering, developing, and selling a wide range of products for both humans and animals. With a diverse product portfolio that includes neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products, Eli Lilly & has established itself as a key player in the healthcare industry. The company’s Smartkarma Smart Scores highlight its potential for growth and resilience in the long term, positioning it well for future success.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma